Luis M. Vilá to Prednisone
This is a "connection" page, showing publications Luis M. Vilá has written about Prednisone.
Connection Strength
0.784
-
V?zquez-Otero I, Medina-Cintr?n N, Arroyo-?vila M, Gonz?lez-Sep?lveda L, Vil? LM. Clinical impact of hydroxychloroquine dose adjustment according to the American Academy of Ophthalmology guidelines in systemic lupus erythematosus. Lupus Sci Med. 2020 05; 7(1).
Score: 0.165
-
Varela-Rosario N, P?rez-Berenguer JL, Vil? LM. Efficacy of immunosuppressive treatment in a systemic lupus erythematosus patient presenting with inclusion body myositis. BMJ Case Rep. 2016 Apr 05; 2016.
Score: 0.125
-
Arroyo-?vila M, Vil? LM. Cardiac tamponade in a patient with mixed connective tissue disease. J Clin Rheumatol. 2015 Jan; 21(1):42-5.
Score: 0.114
-
Rodr?guez-P?rez N, Rodr?guez-Navedo Y, Font YM, Vil? LM. Inflammatory myopathy as the initial presentation of cryoglobulinaemic vasculitis. BMJ Case Rep. 2013 Jun 03; 2013.
Score: 0.102
-
Vil? LM, Molina MJ. Chronic anemia and thrombocytosis as the initial presentation of Still's disease in an elderly patient. Gerontology. 2007; 53(5):289-92.
Score: 0.067
-
Bertoli AM, Font YM, Nadal A, Vil? LM. Differences between active treatment and placebo groups in the study of induction treatment of giant cell arteritis with high-dose glucocorticoids: comment on the article by Mazlumzadeh et al. Arthritis Rheum. 2007 May; 56(5):1723; author reply 1723-4.
Score: 0.067
-
Ugarte-Gil MF, Dubey J, McGwin G, Reveille JD, Vil? LM, Alarc?n GS. Association of Systemic Lupus International Collaborating Clinics Frailty Index With Damage in Systemic Lupus Erythematosus Patients: Results From a Multiethnic, Multicenter US Cohort of Patients With Lupus. Arthritis Care Res (Hoboken). 2023 03; 75(3):585-589.
Score: 0.049
-
Vil? LM, Mayor AM, Silvestrini IE. Therapeutic response and long-term follow-up in a systemic lupus erythematosus patient presenting with Kikuchi's disease. Lupus. 2001; 10(2):126-8.
Score: 0.043
-
Alarc?n GS, Ugarte-Gil MF, Pons-Estel G, Vil? LM, Reveille JD, McGwin G. Remission and low disease activity state (LDAS) are protective of intermediate and long-term outcomes in SLE patients. Results from LUMINA (LXXVIII), a multiethnic, multicenter US cohort. Lupus. 2019 Mar; 28(3):423-426.
Score: 0.038
-
Mart?nez A, Vil? LM, R?os-Olivares E. Predominance of CD4+ T cells and Th2 cytokines in the pericardial fluid of a dermatomyositis patient with cardiac tamponade. Clin Exp Rheumatol. 2004 Jan-Feb; 22(1):135.
Score: 0.013